Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days.


Journal

Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 2 11 2020
pubmed: 3 11 2020
medline: 29 9 2021
Statut: ppublish

Résumé

Prolonged treatment with linezolid (LZD) is known to cause thrombocytopenia. However, some patients do not develop thrombocytopenia despite long-term administration of LZD. To determine the risk factors for LZD-associated thrombocytopenia in patients undergoing long-term LZD therapy, we conducted a retrospective cohort study among 212 patients receiving LZD treatment between December 2011 and June 2014 at a tertiary referral university hospital in Nagoya, Japan. Of the 217 patients who received LZD, 37 were treated with LZD for more than 14 days and were enrolled in the study. We compared data on demographic characteristics, underlying disease, microbiology, concomitant drugs, and laboratory tests between the thrombocytopenia group and the non-thrombocytopenia group. Thrombocytopenia was defined as having a platelet count < 100 × 10

Identifiants

pubmed: 33132425
doi: 10.18999/nagjms.82.3.407
pmc: PMC7548242
doi:

Substances chimiques

Linezolid ISQ9I6J12J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

407-414

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Infection. 2014 Dec;42(6):1007-12
pubmed: 25119433
Ann Intern Med. 2003 Jan 21;138(2):135-42
pubmed: 12529096
Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6
pubmed: 12121967
Antimicrob Agents Chemother. 2010 Nov;54(11):4605-10
pubmed: 20733043
Eur J Clin Pharmacol. 2014 Jan;70(1):23-8
pubmed: 24022332
Antimicrob Agents Chemother. 2002 Mar;46(3):936-7
pubmed: 11850294
Antimicrob Agents Chemother. 2010 Dec;54(12):5418-9
pubmed: 20837753
Clin Infect Dis. 2006 Jan 1;42(1):66-72
pubmed: 16323094
Clin Infect Dis. 2002 Mar 1;34(5):695-8
pubmed: 11803505
Int J Clin Pharm. 2014 Aug;36(4):795-9
pubmed: 24913359
Antimicrob Agents Chemother. 2007 Jul;51(7):2559-63
pubmed: 17470658
JAMA. 2001 Mar 14;285(10):1291
pubmed: 11255382
J Antimicrob Chemother. 2005 Aug;56(2):440-1
pubmed: 15956097
J Antimicrob Chemother. 2002 Jul;50(1):73-7
pubmed: 12096009
Antimicrob Agents Chemother. 2006 Apr;50(4):1599-602
pubmed: 16569895
Int J Antimicrob Agents. 2006 Oct;28(4):345-51
pubmed: 16935472
J Antimicrob Chemother. 2012 Aug;67(8):2034-42
pubmed: 22553142
Clin Infect Dis. 2004 Apr 15;38(8):1058-64
pubmed: 15095207
Antimicrob Agents Chemother. 2011 May;55(5):1867-73
pubmed: 21357301
Clin Ther. 2009 Oct;31(10):2126-33
pubmed: 19922883
Pharmacotherapy. 2002 Jan;22(1):109-12
pubmed: 11794421
Blood. 2010 Sep 23;116(12):2127-33
pubmed: 20530792

Auteurs

Yoshitaka Sato (Y)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Mitsutaka Iguchi (M)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.

Yoshiaki Kato (Y)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.

Hiroshi Morioka (H)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Aki Hirabayashi (A)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Current address: Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Nobuyuki Tetsuka (N)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yuka Tomita (Y)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.

Daizo Kato (D)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Current address: Department of Orthopedics, Okazaki City Hospital, Okazaki, Japan.

Kiyofumi Yamada (K)

Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Japan.

Hiroshi Kimura (H)

Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tetsuya Yagi (T)

Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH